Royalty Pharma Deal History & Licensing Activity
Royalty Pharma is a large biotech headquartered in USA. Over the past three years, Royalty Pharma has been involved in 4 licensing and acquisition transactions, with a primary focus on Antibodies (5 deals).
Deals (12mo)
2
Active Trials
0
Top Modality
Antibodies
Focus Area
Immunology
Royalty Pharma Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Royalty Pharma in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| TEV-53408 | Teva Pharmaceuticals | Antibodies | Phase 2 | license | Jan 2026 |
| litifilimab | Biogen | Antibodies | Phase 3 | collaboration | Jul 2025 |
Royalty Pharma Pipeline Focus
Therapeutic areas and modalities where Royalty Pharma is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Royalty Pharma Strategic Signals
Key indicators of Royalty Pharma's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Royalty Pharma's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Immunology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Dermatology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for dermatology
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
MyosinInhibitor Benchmarks
Upfront, milestone, and royalty benchmarks for myosininhibitor deals
Deal Pulse
About Royalty Pharma Licensing & Deal Activity
Royalty Pharma is a large biotech company based in USA that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, Royalty Pharma ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Royalty Pharma include Immunology (3 deals and trials), Dermatology (2 deals and trials), and Cardiovascular (1 deal and trial). In terms of modality, Royalty Pharma has shown particular interest in antibodies, myosininhibitor.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Royalty Pharma and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Royalty Pharma's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.